Publication in "Breast Cancer Research and Treatment"

Pacylex builds on earlier results showing potential for an NMT inhibitor in lymphoma in breast cancer. Read the press release here: Press release

‍

“Despite the critical role myristoylation plays in cell survival, NMT1 and NMT2 protein levels have never been systematically studied in a large series of human cancers,” said John Mackey, MD, Co-founder and Chief Medical Officer of Pacylex and first author on the paper. “Not only did we find a relationship between NMT2 levels and patient survival, but an NMT inhibitor was generally effective against breast cancer cell lines and inhibited human breast cancers grown in mice.”